Description
Tesamorelin is a synthetic analog of GHRH, consisting of 44 amino acids, molecular formula C221H366N72O67S, molecular weight 5,135.9 g/mol, also known by the research designation TH9507, CAS 218949-48-5.
Structurally, tesamorelin is identical to the first 44 amino acids of naturally occurring human GHRH, but with a trans-3-hexenoic acid group attached to the tyrosine at position 1, designed to increase resistance to enzymatic breakdown. This modification is what separates a research reference compound from an approved drug: tesamorelin, under the brand name Egrifta, was FDA-approved in 2010 for reducing excess visceral adipose tissue in patients with HIV-associated lipodystrophy, based on multiple randomized, placebo-controlled Phase 3 trials. That approval history means tesamorelin has one of the strongest published human clinical trial bases of any peptide in this category, covering effects on visceral fat, IGF-1 levels, and metabolic markers.
The compound is supplied as a lyophilized white to off-white powder, soluble in water, and requires refrigeration after reconstitution. This product is strictly for research purposes only.
PubChem Reference: View compound profile on NIH PubChem
This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
Formula: C221H366N72O67S
Weight: 5135.9 g/mol
CAS: 218949-48-5
Research Designation: TH9507
Tesamorelin in Published Research
Because Egrifta went through full FDA registration trials, tesamorelin has substantially more peer-reviewed human data than most research peptides. Phase 3 trials reported statistically significant reductions in visceral adipose tissue over 26-week treatment periods, along with sustained IGF-1 elevation. Later research has also explored tesamorelin’s effects on cognitive function and hepatic fat in non-alcoholic fatty liver disease, building on the mechanistic and safety foundation established during its original approval studies.
Frequently Asked Questions :
What is Tesamorelin approved for?
FDA-approved as Egrifta for reducing excess visceral fat in HIV-associated lipodystrophy.
What benefits are documented in trials?
Significant visceral fat reduction and sustained IGF-1 elevation across multiple Phase 3 trials.
What is the approved dose?
Egrifta’s approved dose is 2mg subcutaneous daily; this is drug-label data, not a usage instruction for the research compound.
How should it be reconstituted and stored?
Bacteriostatic water, refrigerate after reconstitution.
Where can I buy Tesamorelin for research?
5mg and 10mg kits, HPLC/MS verified, not the branded pharmaceutical.
Sophia B –
I experienced a temporary tracking issue, but support responded quickly and delivery was completed
Emily W –
Excellent experience from start to finish. I highly recommend Peptides Vitals to new customers
Mary Jean –
The package was held up briefly, but it eventually arrived with no problems. Great follow-up from the company
Martinez –
Peptides Vitals has earned my trust through consistent service and quality